Hemasphere

Papers
(The H4-Index of Hemasphere is 28. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)
ArticleCitations
PB1708: CHARACTERIZATION OF GLOBAL CYTOGENOMICS FEATURES IN CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA BY OPTICAL GENOME MAPPING208
P760: PATTERNS OF HYPOMETHYLATING AGENT FAILURE IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES93
P1462: POPULATION-BASED REAL WORLD RESULTS OF CD19-DIRECTED CAR T-CELL THERAPY FOR PATIENTS WITH RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA: A DUTCH CAR T-CELL TUMORBOARD EXPERIENCE90
S233: AXICABTAGENE CILOLEUCEL AS SECOND-LINE THERAPY FOR LARGE B-CELL LYMPHOMA IN TRANSPLANT-INELIGIBLE PATIENTS: FINAL ANALYSIS OF ALYCANTE, A PHASE 2 LYSA STUDY88
PB2064: THE COMPLETE STUDY: A SINGLE ARM, MULTICENTER OBSERVATIONAL STUDY TO EVALUATE EFFECTIVENESS OF PEGCETACOPLAN UNDER REAL WORLD CONDITIONS IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (P67
P401: INNOVATIVE REDUCED-DOSE CHEMOTHERAPY FOLLOWED BY BLINATUMOMAB INDUCTION THERAPY FOR SUCCESSFUL MANAGEMENT OF TREATMENT NAIVE B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA ADULTS: A MULTICENTER, REAL-WORLD58
P1672: OCCUPATIONAL INTEGRATION OF ADULTS WITH SEVERE HAEMOPHILIA (INTHEMO): A STUDY BASED ON THE FRANCECOAG REGISTRY57
P480: DNMT AND HDAC INHIBITION INDUCES IMMUNOGENIC NEOANTIGENS FROM HUMAN ENDOGENOUS RETROVIRAL ELEMENT-DERIVED TRANSCRIPTS56
P1586: COMPARISON OF FREQUENCY OF TRANSFUSION RELATED COMPLICATIONS IN THALASSEMIC AND NON-THALASSEMIC PATIENTS RECEIVING NON LEUKODEPLETED RED CELL CONCENTRATE.52
P1571: PREVENTION OF COVID19 IN PATIENTS WITH HEMOBLASTOSIS. OWN CLINICAL EXPERIENCE51
P987: IRAK1 AND JAK2 DUAL INHIBITION WITH PACRITINIB PREVENTS MYELOFIBROSIS-LIKE PHENOTYPE IN AN INFLAMMATION-DRIVEN MURINE MODEL48
PB1784: CLADRIBINE SYNERGIZES THE EFFECT OF VENETOCLAX ON CELL PROLIFERATION ARREST AND APOPTOSIS BY TARGETING DNA-PKCS/C-MYC SIGNALING IN ACUTE MYELOID LEUKEMIA42
P529: THE EFFECT OF AGE AND TREATMENT ON THE PREDICTIVE VALUE OF MEASURABLE RESIDUAL DISEASE: IMPLICATIONS FOR THE CLINICAL MANAGEMENT OF ADULT PATIENTS WITH ACUTE MYELOID LEUKEMIA38
PB2525: A FOUR YEARS’ EXPERIENCE OF UNIVERSAL NEWBORN SCREENING FOR HAEMOGLOBIN DISORDERS IN UDINE, FVG, NORTHERN ITALY38
P1453: ORTHOTOPIC LIVER TRANSPLANT IN SICILIAN HEMOGLOBINOPHATIES PATIENTS37
P404: IMMUNOGLOBULIN GENE REARRANGEMENT IN KOREAN PATIENTS WITH B-LYMPHOBLASTIC LEUKEMIA – AN IMMUNOPHENOTYPE AND REPERTOIRE ANALYSIS35
P1093: MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC) OF ZANUBRUTINIB (ZANU) VERSUS IBRUTINIB (IBRU) IN RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA (R/R MZL)33
PB2193: JAK2 V617F MUTATION BURDEN DETECTION AND RELATIONSHIP WITH LABORATORY CHARACTERISTICS IN MYELOPROLIFERATIVE NEOPLASMS33
P1671: CARFILZOMIB-DEXAMETHASONE MAINTENANCE HAMPERS RECOVERY AFTER SALVAGE AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH MULTIPLE MYELOMA32
P702: APPLICATION OF NEXT GENERATION SEQUENCING (NGS) FOR MINIMAL RESIDUAL DISEASE (MRD) AND CHIMERISM MONITORING IN MYELODYSPLASTIC SYNDROME (MDS) AFTER ALLOGENIC STEM CELL TRANSPLANTATION (ASCT)32
PB2163: BORTEZOMIB - CYCLOPHOSPHAMIDE – DEXAMETHASONE (VCD) REGIMEN IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) - EXPERIENCE FROM A RESOURCE CONSTRAINT SETTING IN SOUTH INDIA32
PB2390: STUDY OF GENETIC ALTERATIONS USING A CUSTOM LYMPHOID TARGETED NGS PANEL IN PATIENTS WITH FOLLICULAR LYMPHOMA: A PILOT STUDY31
P1147: FEASIBILITY AND OUTCOME AFTER DOSE REDUCTION OF IMMUNOCHEMOTHERAPY IN YOUNG ADULTS WITH BURKITT LYMPHOMA AND LEUKEMIA. RESULTS OF THE BURKIMAB14 TRIAL30
PB2381: EFFICACY ANALYSIS OF BRUTON’S TYROSINE KINASE INHIBITOR COMBINED REGIMEN IN THE TREATMENT OF ELDERLY PATIENTS WITH RELAPSED/REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA30
PB2203: INCIDENCE AND PREVALENCE OF MYELOFIBROSIS IN GERMANY: A RETROSPECTIVE CLAIMS DATA ANALYSIS30
P1445: THE IMPACT OF ILLNESS PERCEPTION AND STIGMA ON PATIENT-REPORTED OUTCOMES IN SICKLE CELL DISEASE30
B07 HIGH EXPRESSION OF NUCLEAR CEREBLON IS ASSOCIATED WITH LONGER SURVIVAL IN PATIENTS WITH MULTIPLE MYELOMA TREATED WITH IMIDS29
P1033: JAKTINIB IN PATIENTS WITH MYELOFIBROSIS WHO WERE REFRACTORY OR RELAPSED TO RUXOLITINIB: A SINGLE-ARM, OPEN-LABEL, MULTICENTER, PHASE 2 STUDY29
S304: WHAT IS A MASSIVE TRANSFUSION? A SCOPING REVIEW TO INFORM AN INTERNATIONAL CONSENSUS DEFINITION28
P1683: THE EORTC QLQ-HL27: EORTC PROSPECTIVE INTERNATIONAL VALIDATION OF A DISEASE-SPECIFIC QUESTIONNAIRE FOR ASSESSMENT OF HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH HODGKIN LYMPHOMA28
PB2226: HIGH RISK LANGERHANS CELL HISTIOCYTOSIS (LCH) IN CHILDREN: THE ROLE OF CLADRIBINE SALVAGE IN IMPROVING THE OUTCOME. A SINGLE CENTER EXPERIENCE28
0.10085606575012